- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Nephrolithiasis.
Displaying page 1 of 2.
EudraCT Number: 2014-000308-82 | Sponsor Protocol Number: oxalate01 | Start Date*: 2017-02-08 |
Sponsor Name:Universitair Ziekenhuis Brussel | ||
Full Title: Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial | ||
Medical condition: Urolithiasis and secondary hyperoxaluria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015217-52 | Sponsor Protocol Number: Uni-Koeln-1251 | Start Date*: 2010-06-08 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - Pilot trial on treatment of patients with primary hyperoxaluria type I with pyridoxal-phosphate | |||||||||||||
Medical condition: In this study we will prospectively analyze the reduction of urinary oxalate excretion under the treatment with PLP in dosages of 5mg/kg/day up to 20 mg/kg/day and serum level response relationship... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001930-26 | Sponsor Protocol Number: LEOC/FJD-14/01 | Start Date*: 2014-10-10 | |||||||||||
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ | |||||||||||||
Full Title: A randomized, evaluator blinded clinical trial to compare clinical efficacy of four different analgesic strategies in patients undergoing Extracorporeal Shock Wave Lithotripsy (ESWL). | |||||||||||||
Medical condition: Pain in Nephrolithiasis in whom Extracorporeal shock wave lithotripsy is indicated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001486-21 | Sponsor Protocol Number: 276046 | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:University of Helsinki/CLUE working Group | |||||||||||||
Full Title: A Multicentre Randomised Control Trial Assessing the Efficacy of Antimicrobial Prophylaxis for Extracorporeal Shock Wave Lithotripsy on reducing Urinary Tract Infections | |||||||||||||
Medical condition: Nephrolithiasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015817-31 | Sponsor Protocol Number: OC3-DB-02 | Start Date*: 2009-12-01 | |||||||||||
Sponsor Name:OxThera IP AB | |||||||||||||
Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria | |||||||||||||
Medical condition: primary hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003372-73 | Sponsor Protocol Number: ZTI-01-200 | Start Date*: 2016-04-11 | ||||||||||||||||
Sponsor Name:Zavante Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 Versus Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, In... | ||||||||||||||||||
Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) HU (Completed) LT (Completed) LV (Completed) SK (Completed) PL (Completed) EE (Completed) GR (Completed) BG (Completed) RO (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001510-20 | Sponsor Protocol Number: 180987 | Start Date*: 2016-06-21 | |||||||||||
Sponsor Name:Aalborg University Hospital | |||||||||||||
Full Title: Treatment of Primary Hyperparathyroidism with Denosumab and Cinacalcet | |||||||||||||
Medical condition: Primary Hyperparathyroidism. Patients included will have Osteopenia/Osteoporosis with a T-score between -1,0 and 3,5. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003011-97 | Sponsor Protocol Number: 69HCL20_0071 | Start Date*: 2020-12-14 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Fluconazole as a new therapeutic tool in hypercalciuric patients with increased 1,25(OH)2D levels. | |||||||||||||
Medical condition: Hypercalciuria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001635-23 | Sponsor Protocol Number: TMC114IFD3003 | Start Date*: 2012-01-17 | |||||||||||
Sponsor Name:Janssen Cilag International N.V. | |||||||||||||
Full Title: PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IE (Completed) DE (Completed) ES (Completed) AT (Completed) HU (Completed) DK (Completed) IT (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004556-38 | Sponsor Protocol Number: TP-434-010 | Start Date*: 2014-02-24 | |||||||||||
Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated Urinary Tract Infections | |||||||||||||
Medical condition: Complicated urinary tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) IT (Completed) EE (Completed) CZ (Completed) LV (Completed) GR (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003671-35 | Sponsor Protocol Number: SPR994-301 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:Spero Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) ... | |||||||||||||
Medical condition: complicated urinary tract infection or acute pyelonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) BG (Completed) HU (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006437-40 | Sponsor Protocol Number: TMC114HIV3006 | Start Date*: 2007-02-05 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) HU (Completed) DK (Completed) DE (Completed) PT (Completed) ES (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002383-34 | Sponsor Protocol Number: TMC114HIV3017 | Start Date*: 2008-10-09 | |||||||||||
Sponsor Name:JANSSEN-CILAG | |||||||||||||
Full Title: A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple... | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022487-12 | Sponsor Protocol Number: CXL-MD-02 | Start Date*: 2011-02-25 | |||||||||||
Sponsor Name:Cerexa, Inc | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline fosamil and NXL104 Versus Intravenous Doripenem in ... | |||||||||||||
Medical condition: Complicated Urinary Tract Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002207-26 | Sponsor Protocol Number: TP-434-021 | Start Date*: 2016-12-15 | |||||||||||
Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections | |||||||||||||
Medical condition: Complicated Urinary Tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) AT (Completed) SK (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005117-31 | Sponsor Protocol Number: W-4282-301 | Start Date*: 2018-10-17 | ||||||||||||||||
Sponsor Name:Wockhardt Bio AG | ||||||||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem followed by Optional Oral Therapy in the Treatment of... | ||||||||||||||||||
Medical condition: Complicated urinary tract infection or acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Temporarily Halted) BG (Temporarily Halted) LV (Completed) LT (Temporarily Halted) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000914-76 | Sponsor Protocol Number: 1409R2121 | Start Date*: 2014-11-24 | |||||||||||
Sponsor Name:Shionogi Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Unc... | |||||||||||||
Medical condition: Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis caused by Gram-negative Pathogens | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed) DE (Completed) PL (Completed) RO (Completed) HR (Completed) LV (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003772-31 | Sponsor Protocol Number: IT001-302 | Start Date*: 2018-12-07 |
Sponsor Name:Iterum Therapeutics International Limited | ||
Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe... | ||
Medical condition: Complicated urinary tract infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) EE (Completed) CZ (Completed) BG (Completed) SK (Completed) HR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002608-29 | Sponsor Protocol Number: CS2514-2017-0003 | Start Date*: 2017-12-12 | ||||||||||||||||
Sponsor Name:Entasis Therapeutics | ||||||||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infe... | ||||||||||||||||||
Medical condition: Complicated Urinary Tract Infection including Acute Pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001896-19 | Sponsor Protocol Number: P2-IMU-838-MS | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and t... | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) DE (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
